8月28日，麦澜德跌1.51%，成交额1.51亿元。两融数据显示，当日麦澜德获融资买入额1469.10万元， 融资偿还2295.45万元，融资净买入-826.35万元。截至8月28日，麦澜德融资融券余额合计1.59亿元。 分红方面，麦澜德A股上市后累计派现2.68亿元。 机构持仓方面，截止2025年6月30日，麦澜德十大流通股东中，华夏稳增混合（519029）位居第三大流 通股东，持股125.21万股，相比上期增加14.17万股。中信建投轮换混合A（003822）位居第五大流通股 东，持股65.62万股，为新进股东。中信建投甄选混合A（008347）位居第七大流通股东，持股56.33万 股，为新进股东。汇添富成长焦点混合（519068）位居第十大流通股东，持股36.38万股，相比上期减 少29.94万股。汇添富医药保健混合（470006）、国泰医药健康股票A（009805）、融通健康产业灵活配 置混合A/B（000727）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日， ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of 麦澜德 in the medical device industry, showcasing its recent achievements and financial metrics [1][2] - 麦澜德's stock closed at 29.62 yuan, with a rolling PE ratio of 28.17, marking a new low in 32 days, and a total market capitalization of 29.62 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE ratio of 49.20 and a median of 36.56 [1][2] Group 2 - For Q1 2025, 麦澜德 reported revenue of 1.18 billion yuan, reflecting a year-on-year increase of 13.36%, and a net profit of 3985.97 million yuan, up by 9.85%, with a gross margin of 70.85% [2] - The company specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on women's health [1] - 麦澜德 has been recognized as a "national manufacturing single champion" and is the first national-level specialized and innovative "little giant" enterprise in its field, indicating strong market competitiveness and innovation capabilities [1]